BioLineRx (BLRX) Return on Capital Employed (2013 - 2025)
BioLineRx's (BLRX) quarterly Return on Capital Employed came in at 36.44% in Q4 2025, up 3065.0% year-on-year from 1.15% in Q4 2024, and up 10.36% quarter-over-quarter from 40.65% in Q3 2025.
BioLineRx (BLRX) Return on Capital Employed (2013 - 2025) Analysis & Trends
BioLineRx's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 36.44% for Q4 2025.
- On a quarterly basis, Return on Capital Employed rose 3065.0% year-over-year to 36.44% in Q4 2025; TTM through Dec 2025 was 36.44%, a 3065.0% increase from a year earlier, with the FY2025 full-year figure at 37.03%, up 1965.0% from the prior year.
- Return on Capital Employed rose to 36.44% in Q4 2025 per BLRX's latest filing, from 40.65% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.99% in Q2 2021 and bottomed at 318.43% in Q4 2023.
- The 5-year median for Return on Capital Employed is 47.47% (2022), against an average of 75.88%.
- Across the five-year window, Return on Capital Employed tumbled 27577 bps in 2023 and surged 25134 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 33.29% in 2021, then declined by 28 bps to 42.66% in 2022, then plunged by 646 bps to 318.43% in 2023, then soared by 79 bps to 67.09% in 2024, then surged by 46 bps to 36.44% in 2025.
- Per Business Quant, the three latest BLRX Return on Capital Employed figures stand at 36.44% (Q4 2025), 40.65% (Q3 2025), and 51.98% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 | -36.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -36.44% |
| Sep 30, 2025 | -40.65% |
| Jun 30, 2025 | -51.98% |
| Mar 31, 2025 | -66.15% |
| Dec 31, 2024 | -67.09% |
| Sep 30, 2024 | -102.50% |
| Jun 30, 2024 | -150.53% |
| Mar 31, 2024 | -173.02% |
| Dec 31, 2023 | -318.43% |
| Sep 30, 2023 | -96.01% |
| Jun 30, 2023 | -66.70% |
| Mar 31, 2023 | -52.81% |
| Dec 31, 2022 | -42.66% |
| Sep 30, 2022 | -41.06% |
| Jun 30, 2022 | -42.96% |
| Mar 31, 2022 | -36.83% |
| Dec 31, 2021 | -33.29% |
| Sep 30, 2021 | -30.52% |
| Jun 30, 2021 | -28.99% |
| Mar 31, 2021 | -38.99% |